Empagliflozin
- Generic Name
- Empagliflozin
- Brand Names
- Glyxambi, Jardiance, Synjardy, Trijardy
- Drug Type
- Small Molecule
- Chemical Formula
- C23H27ClO7
- CAS Number
- 864070-44-0
- Unique Ingredient Identifier
- HDC1R2M35U
- Background
Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies, for the management of type 2 diabetes mellitus.
...
- Indication
Empagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes, either alone or in combination with metformin or linagliptin. It is also indicated to reduce the risk of cardiovascular death in adult patients with both type 2 diabetes mellitus and established cardiovascular disease, either alone or a...
- Associated Conditions
- Cardiovascular Mortality, Chronic Kidney Disease (CKD), End Stage Renal Disease (ESRD), Hospitalizations, Symptomatic Congestive Heart Failure, Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate
- Associated Therapies
- Monotherapy
Effects of Empagliflozin on Exercise Capacity and Left Ventricular Diastolic Function in Patients With Heart Failure With Preserved Ejection Fraction and Type-2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2018-11-26
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
- Target Recruit Count
- 70
- Registration Number
- NCT03753087
- Locations
- 🇷🇺
National Medical Research Center for Cardiology, Moscow, Russian Federation
Head-to-head Comparison of Empagliflozin and Dapagliflozin
- First Posted Date
- 2018-11-21
- Last Posted Date
- 2022-07-20
- Lead Sponsor
- Chungbuk National University Hospital
- Target Recruit Count
- 600
- Registration Number
- NCT03748810
- Locations
- 🇰🇷
Chungbuk National University Hospital, Cheonju, Chungcheongbuk-do, Korea, Republic of
Comparison of The Effects of Thiazolidinediones(TZD), Sodium- Glucose Cotransporter 2 Inhibitors(SGLT2i) Alone and TZD / SGLT2i Combination Therapy on Non-alcoholic Fatty Liver Disease in Type 2 Diabetic Patients With Fatty Liver
- Conditions
- MASLD - Metabolic Dysfunction-Associated Steatotic Liver DiseaseType 2 DiabetesDigestive System DiseaseLiver DiseasesFatty LiverMetabolic Dysfunction-Associated Steatotic Liver DiseaseNon-Alcoholic Fatty Liver DiseaseHypoglycemic AgentsPhysiological Effects of DrugsSodium-Glucose Cotransporter 2 Inhibitors
- Interventions
- First Posted Date
- 2018-08-24
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 60
- Registration Number
- NCT03646292
- Locations
- 🇰🇷
Department of Internal Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea, Seoul, Korea, Republic of
Efficacy and Safety of Empagliflozin in NODAT
- Conditions
- Interventions
- First Posted Date
- 2018-08-22
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 6
- Registration Number
- NCT03642184
- Locations
- 🇨🇳
Department of nephrology, endocrinology and kidney transplantation , Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
This Study in Healthy People Tests Whether Taking a Low Strength of Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills
- Conditions
- Interventions
- First Posted Date
- 2018-08-14
- Last Posted Date
- 2020-02-21
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 30
- Registration Number
- NCT03629054
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)
- Conditions
- Interventions
- First Posted Date
- 2018-07-20
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 6609
- Registration Number
- NCT03594110
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸Cedar Crosse Research Center, Chicago, Illinois, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
Empagliflozin on Cardiac-renal Injury in Patients With STEAMI Patients After Primary PCI
- Conditions
- Interventions
- First Posted Date
- 2018-07-19
- Last Posted Date
- 2018-07-19
- Lead Sponsor
- Chinese PLA General Hospital
- Target Recruit Count
- 128
- Registration Number
- NCT03591991
Gemigliptin, Dapagliflozin, Empagliflozin DDI Study
- Conditions
- Interventions
- First Posted Date
- 2018-06-21
- Last Posted Date
- 2018-06-21
- Lead Sponsor
- LG Chem
- Target Recruit Count
- 48
- Registration Number
- NCT03565458
- Locations
- 🇰🇷
LG chem, Seoul, Gangseo-Gu, Korea, Republic of
EMPA Acute Heart Failure
- Conditions
- Interventions
- First Posted Date
- 2018-06-13
- Last Posted Date
- 2022-10-27
- Lead Sponsor
- RWTH Aachen University
- Target Recruit Count
- 19
- Registration Number
- NCT03554200
- Locations
- 🇩🇪
Department of Internal Medicine I RWTH Aachen University Hospital, Aachen, NRW, Germany
Rotation for Optimal Targeting of Albuminuria and Treatment Evaluation (ROTATE-2)
- Conditions
- Interventions
- First Posted Date
- 2018-04-20
- Last Posted Date
- 2018-09-14
- Lead Sponsor
- Steno Diabetes Center Copenhagen
- Registration Number
- NCT03504566
- Locations
- 🇩🇰
Steno Diabetes Center Copenhagen, Gentofte, Denmark
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.